On September 22, 2025, the Trump Administration announced new health guidance regarding potential risks associated with acetaminophen use during pregnancy. This guidance is based on evidence suggesting that in utero exposure to acetaminophen may be linked to long-term neurological effects, including an increased risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). The announcement follows findings from large cohort studies and a review conducted by researchers at Harvard University, indicating a concerning correlation between prenatal acetaminophen exposure and neurodevelopmental disorders in children.

The Administration’s statement emphasized the importance of utilizing robust scientific evidence to understand the root causes of autism, which has seen a significant rise in diagnoses over the past two decades. Alongside the new guidance, President Trump mentioned the approval of a new treatment option aimed at alleviating some symptoms of autism. This initiative reflects the Administration’s commitment to addressing the autism epidemic and improving health outcomes for affected families.

In response to these findings, experts have called for precautionary measures regarding acetaminophen use during pregnancy, recommending that pregnant women minimize their exposure. The announcement has sparked both support and criticism, with the Administration urging the public to focus on the scientific evidence presented, while acknowledging the challenges posed by misinformation in the media. As research continues, these developments highlight the ongoing efforts to tackle complex health issues related to autism.

Original: article